CN1946383A - 基于天然雌激素的多段式避孕制剂 - Google Patents
基于天然雌激素的多段式避孕制剂 Download PDFInfo
- Publication number
- CN1946383A CN1946383A CNA2005800125561A CN200580012556A CN1946383A CN 1946383 A CN1946383 A CN 1946383A CN A2005800125561 A CNA2005800125561 A CN A2005800125561A CN 200580012556 A CN200580012556 A CN 200580012556A CN 1946383 A CN1946383 A CN 1946383A
- Authority
- CN
- China
- Prior art keywords
- daily dose
- dose unit
- contain
- dosage
- estradiol valerate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Steroid Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
本发明涉及一种基于天然雌激素和合成孕激素的多段式避孕制剂。与经过长期和广泛的使用已被证明为可靠和安全的排卵抑制剂相比，本发明的多段式制剂避孕在整个周期持续时间内可靠性更高，改善了周期性出血，同时使副作用如乳房触痛、头痛、情绪低落和性欲改变等最小化或消除。
Description
技术领域
本发明涉及一种基于天然雌激素和合成孕激素的多段式避孕制剂。
与经过长期和广泛的使用已被证明为可靠和安全的通过抑制排卵进行避孕的常规产品相比，本发明的多段式制剂避孕在整个周期持续时间内可靠性更高，改善了周期性出血，同时使副作用如乳房触痛、头痛、情绪低落和性欲改变等最小化或消除。
背景技术
专利文献中公开了基于天然雌激素和孕激素之组合的多段式避孕产品。
EP 0 770 388 B1中描述了一种多段式避孕产品，其中第一阶段由2至4个日剂量单元组成，并且每个日剂量单元中含有的活性成分全部为天然雌激素。该多段式产品的第二阶段由两组含有至少一种天然雌激素和至少一种合成孕激素的日剂量单元组成。在此，所述第一组由5至3个日剂量单元组成，而第二组由17至13个日剂量单元组成。第三阶段由2至4个日剂量单元组成，并且每个日剂量单元中含有的活性成分全部是天然雌激素。各阶段中天然雌激素的日剂量保持不变，但从第1至第3阶段依次递减。第二阶段中，第二组中合成或天然孕激素的比例大于第一组的比例。最后一个阶段由2至4个日剂量单元组成，并且每个日剂量单元中的活性成分是药学可接受的安慰剂。
在实施例5中列出了一种戊酸雌二醇和地诺孕素的组合。在此情况下，第一阶段为3个含有3mg戊酸雌二醇的日剂量单元，在第二阶段中，第一组为4个含有2mg戊酸雌二醇和1mg地诺孕素的日剂量单元，第二组为16个含有2mg戊酸雌二醇和2mg地诺孕素的日剂量单元，而第三阶段为2个含有1mg戊酸雌二醇的日剂量单元。最后一个阶段为3个含有药学可接受的安慰剂的日剂量单元。
为获得避孕可靠性的信息，采用放射免疫方法测定黄体酮的血清浓度。该专利所报道的黄体酮浓度为4.0ng/ml。从第一个给药周期至最后一个给药周期，不规则出血(突破性出血和点滴出血)的平均比例下降45至53％。
此外，现已查明组合制剂的避孕可靠性源自雌激素和孕激素这两种成分的作用。
现已查明抑制排卵需要每天使用1mg地诺孕素(Dienogest：Prklinikund Klinik eines neuen Gestagens，edited by A.T.Teichmann，Walter deGruyter Berlin/New York(1995)，p.101)和2.0-3.0mg屈螺酮(Rosenbaum P，Schmidt W，Helmerhorst F M et a1.，Inhibition of ovulationby a novel progestogen(drospirenone)…，Eur contracept.Reprod.HealthCare 5：16-24(2000))。
此外，TAUBERT，H.D.和KUHL，H.(Kontrazeption mit Hormonen，editors Taubert，H.-D.et al.，Georg Thieme Verlag Stuttgart/New York(1995)，p.160)指出不规则出血的发生率与雌激素，如炔雌醇或孕激素的血清浓度低之间没有必然的联系。
发明内容
因此，本发明的目的是提供一种基于天然雌激素的激素类避孕组合物，与常规通过抑制排卵进行避孕的产品相比，在整个周期的持续时间内本发明的多段式制剂的避孕可靠性更高，改善了周期性出血，同时使副作用如乳房触痛、头痛、情绪低落和性欲改变等最小化或消除。采用一种多段式避孕产品可以达到这一目的，在该多段式避孕产品中，第一阶段由2个含有3mg天然雌激素戊酸雌二醇的日剂量单元组成。第二阶段由两组日剂量单元组成，其中第一组包含5个含有2mg戊酸雌二醇和一种合成孕激素之组合的日剂量单元，其中该孕激素的剂量是抑制排卵剂量的至少2倍或3倍。该第二阶段的第二组由17个含有2mg戊酸雌二醇和一种合成孕激素之组合的日剂量单元组成，其中该孕激素的剂量是抑制排卵剂量的至少3倍或4倍。第三阶段包含2个含有1mg戊酸雌二醇的日剂量单元。最后一阶段为2个含有药学可接受的安慰剂的日剂量单元。
优选地，合成孕激素活性的成分，如地诺孕素、屈螺酮或某种孕激素的剂量至少是已知排卵抑制剂量的2倍。
本发明的多段式避孕产品特别适用于口服给药，但也可以采用阴道内给药、非肠道给药，包括局部给药、直肠给药、经鼻给药、口内给药或舌下给药等形式。
通过已知的方法，采用与所需给药形式相适应的制药技术中常规使用的固体或液体载体或稀释剂以及辅料，按所需剂量制备多段式避孕产品。
片、薄膜衣片、糖衣片或明胶硬胶囊优选用于口服给药。
具体实施方式
以下通过实施例对本发明进行说明。在本节中重点讨论避孕可靠性，周期性出血以及给药耐受性等问题。
避孕可靠性
避孕可靠性主要通过Hoogland评分加以确定，根据卵泡大小、雌二醇水平以及孕激素浓度给出Hoogland评分。在本发明中，采用放射免疫方法测定月经周期中指定时间点的黄体酮血清浓度，并且测定排卯数目(Hoogland评分为6)以及黄体化未破裂卵泡数目(Hoogland评分为5)。
周期稳定性
根据每个周期中记录的出血特性评价周期稳定性。重点是记录不规则出血的发生率(突破性出血和点滴出血)。对记录的方式进行标准化。数据被描述性地进行分析。
耐受性
根据主官感受如头痛、情绪低落、乳房触痛、胃部不适(恶心/呕吐)、水肿以及性欲改变评价耐受性。
实施例1
用药方案如下：
第1至2天：每日3mg戊酸雌二醇；
第3至7天：每日2mg戊酸雌二醇+2mg地诺孕素；
第8至24天：每日2mg戊酸雌二醇+3mg地诺孕素；
第25至26天：每日1mg戊酸雌二醇；
第27至28天：安慰剂。
93名女性参与了本项研究，年龄段为18至35岁。每人参与3次给药周期，对第2和第3个给药周期进行观察。
在第2个周期中(主实验期)，93名妇女中有3人排卵(3.23％)，在第3个给药周期中，93名妇女中有2人排卵。
因此，本发明给药方案抑制排卵的可靠性为96.77％。
同时，本发明的给药方案也表现出了良好的耐受性。
实施例2
用药方案如下：
第1至2天：每日3mg戊酸雌二醇；
第3至7天：每日2mg戊酸雌二醇+3mg地诺孕素；
第8至24天：每日2mg戊酸雌二醇+4mg地诺孕素；
第25至26天：每日1mg戊酸雌二醇；
第27至28天：安慰剂。
93名女性参与了本项研究，年龄段为18至35岁。每人参与3次给药周期，对第2和第3个给药周期进行观察。
在第2个给药周期中(主实验期)，93名妇女中有2人排卵(2.15％)，在第3个给药周期中，92名妇女中有2人排卵。
因此，本发明给药方案抑制排卵的可靠性为97.85％。
同时，本发明的给药方案也表现出了良好的耐受性。
两个实施例所观察到的有效排卵抑制率分别为97.85％和96.77％。在近期的有关常规排卵抑制剂的研究中(Pierson R A et al.，“OrthoEvra/Evra versus oral contraceptives：follicular development…”，Fertil.Steril.80(1)，pp.34-42(2003))，实验结果证明即使是经过长期和广泛使用后被证明是可靠和安全的产品，排卵也占有一定的百分比。在第2个给药周期中，采用含有左炔诺孕酮的三段式口服避孕产品的排卵率为14％(22名实验对象中有3人排卵)，采用含有左炔诺孕酮的一段式口服避孕产品时，25名实验对象中有6人排卵，而采用含有诺孕酯的三段式口服避孕产品的排卵率为16％(25名实验对象中有4人排卵)。这些数值与以上本发明产品所获得的效果明显不同，说明本发明产品的可靠性要高于Pierson等人所论述的避孕可靠性。
Claims (2)
1、基于天然雌激素和合成孕激素之组合的多段式避孕产品，其特征在于
第一阶段由2个含有3mg天然雌激素戊酸雌二醇的日剂量单元组成，
第二阶段由两组日剂量单元组成，其中第一组由5个含有2mg戊酸雌二醇和一种合成孕激素之组合的日剂量单元组成，其中该孕激素的剂量是抑制排卵剂量的至少2倍或3倍，而第二组由17个含有2mg戊酸雌二醇和一种合成孕激素之组合的日剂量单元组成，其中该孕激素的剂量是抑制排卵剂量的至少3倍或4倍，
第三阶段由2个含有1mg戊酸雌二醇的日剂量单元组成，以及
另外一个阶段由2个含有药学可接受的安慰剂的日剂量单元组成。
2、如权利要求1所述的多段式避孕产品，其特征在于所述合成孕激素活性成分为地诺孕素、屈螺酮或某种孕激素，其剂量至少是已知排卵抑制剂量的2倍。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004019743.1 | 2004-04-20 | ||
| DE102004019743A DE102004019743B4 (de) | 2004-04-20 | 2004-04-20 | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| PCT/EP2005/004022 WO2005102247A2 (de) | 2004-04-20 | 2005-04-15 | Mehrphasenpräparat zur kontrazeption auf der basis eines natürlichen estrogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1946383A true CN1946383A (zh) | 2007-04-11 |
| CN1946383B CN1946383B (zh) | 2010-06-09 |
Family
ID=34979546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800125561A Active CN1946383B (zh) | 2004-04-20 | 2005-04-15 | 基于天然雌激素的多段式避孕制剂 |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US8071577B2 (zh) |
| EP (1) | EP1740163B2 (zh) |
| JP (1) | JP4908399B2 (zh) |
| KR (1) | KR20060134168A (zh) |
| CN (1) | CN1946383B (zh) |
| AR (2) | AR048830A1 (zh) |
| AT (1) | ATE473734T1 (zh) |
| AU (1) | AU2005235418C1 (zh) |
| BR (1) | BRPI0510005A (zh) |
| CA (1) | CA2561839C (zh) |
| CR (1) | CR8695A (zh) |
| CY (1) | CY1111292T1 (zh) |
| DE (2) | DE102004019743B4 (zh) |
| DK (1) | DK1740163T4 (zh) |
| EA (1) | EA010313B1 (zh) |
| EC (1) | ECSP067000A (zh) |
| ES (1) | ES2348038T5 (zh) |
| GT (1) | GT200500093A (zh) |
| HK (1) | HK1099701A1 (zh) |
| HR (1) | HRP20100513T4 (zh) |
| IL (2) | IL178510A (zh) |
| ME (1) | ME01183B (zh) |
| MX (1) | MXPA06012213A (zh) |
| MY (1) | MY143669A (zh) |
| NO (1) | NO344098B1 (zh) |
| NZ (1) | NZ550417A (zh) |
| PA (1) | PA8630901A1 (zh) |
| PE (1) | PE20060308A1 (zh) |
| PL (1) | PL1740163T5 (zh) |
| PT (1) | PT1740163E (zh) |
| RS (1) | RS51434B2 (zh) |
| SI (1) | SI1740163T2 (zh) |
| SV (1) | SV2006002090A (zh) |
| TW (1) | TWI351960B (zh) |
| UA (1) | UA83915C2 (zh) |
| UY (1) | UY28863A1 (zh) |
| WO (1) | WO2005102247A2 (zh) |
| ZA (1) | ZA200609594B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004019743B4 (de) * | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| ATE546144T1 (de) * | 2005-10-13 | 2012-03-15 | Bayer Pharma AG | Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysf unktionellen uterinen blutung in einheit mit einer oralen kontrazeption |
| ATE424828T1 (de) * | 2005-10-13 | 2009-03-15 | Bayer Schering Pharma Ag | Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| ES2558030T3 (es) | 2006-03-02 | 2016-02-01 | Warner Chilcott Company, Llc | Método anticonceptivo oral multifásico de ciclo prolongado |
| DE102006010329A1 (de) * | 2006-03-06 | 2007-09-13 | Höltge, Michael, Dipl.-Med. | Hormonelles Kontrazeptivum auf der Basis eines Estrogens, eines Gestagens oder einer Kombination von Estrogenen und Gestagenen unter der Zugabe von Testosteron |
| EP1930010A1 (de) * | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
| US20090117183A1 (en) * | 2007-11-05 | 2009-05-07 | Sabine Fricke | Oral contraceptive containing a gestagen and an estrogen combined with pharmaceutically acceptable auxiliary agents and/or excipients, but not containing lactose, and method of making same |
| WO2012155091A1 (en) * | 2011-05-11 | 2012-11-15 | Kirax Corporation | Package for improved treatment of conditions |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4168068A (en) | 1969-07-22 | 1971-01-28 | Unisearch Limited | Improvements in or relating to oral contraceptives |
| US3639600A (en) | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
| US3795734A (en) | 1970-04-20 | 1974-03-05 | American Home Prod | Cyclic regimen of hormone administration for contraception |
| US4066757A (en) | 1973-03-26 | 1978-01-03 | Ortho Pharmaceutical Corporation | Oral contraceptive regimen |
| DE2365103C3 (de) | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | V erwendung von Hormonen zur Kontrazeption |
| DE2431704A1 (de) | 1974-07-02 | 1976-01-22 | Asche Ag | Stufenkombinationspraeparate per kontrazeption |
| DE2645307A1 (de) | 1976-10-05 | 1978-04-06 | Schering Ag | Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen |
| JPS6019734B2 (ja) | 1977-05-12 | 1985-05-17 | 三共株式会社 | 安定なプロスタグランジンｅ類製剤の製法 |
| US4272270A (en) | 1979-04-04 | 1981-06-09 | Petrochem Consultants, Inc. | Cryogenic recovery of liquid hydrocarbons from hydrogen-rich |
| NL8001593A (nl) * | 1980-03-18 | 1981-10-16 | Akzo Nv | Meerfasisch combinatiepreparaat voor orale anticonceptie. |
| US4390531A (en) | 1981-08-10 | 1983-06-28 | Syntex Pharmaceuticals International Ltd. | Method of contraception using peak progestogen dosage |
| US4921843A (en) | 1988-10-20 | 1990-05-01 | Pasquale Samuel A | Contraception system and method |
| US4628051A (en) | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4544554A (en) | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4530839A (en) | 1983-09-26 | 1985-07-23 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4616006A (en) | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| DE3341638A1 (de) | 1983-11-17 | 1984-05-03 | Hermann Dr.rer.nat. 8000 München Heßlinger | Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol |
| DE3347125A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption |
| AU581486B2 (en) | 1985-12-30 | 1989-02-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
| DK174724B1 (da) | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
| CA2005933A1 (en) | 1989-01-09 | 1990-07-09 | Jesse Hipps, Sr. | Photohardenable composition containing five member aromatic group with imine moiety |
| IE71203B1 (en) * | 1990-12-13 | 1997-02-12 | Akzo Nv | Low estrogen oral contraceptives |
| DE4104385C1 (zh) | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
| DE4224534A1 (de) | 1992-07-24 | 1994-01-27 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
| DE4308406C1 (de) | 1993-03-12 | 1994-06-16 | Jenapharm Gmbh | Kombinationspräparat zur Kontrazeption |
| DE4313926A1 (de) * | 1993-04-28 | 1994-11-03 | Jenapharm Gmbh | Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption |
| DE4339934C2 (de) | 1993-05-07 | 1995-05-24 | Klaus Dr Med Umbreit | Ovulationshemmendes Mittel zur hormonalen Kontrazeption |
| NL9301562A (nl) | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| US20050032756A1 (en) | 1995-10-28 | 2005-02-10 | Michael Dittgen | Multistage preparation for contraception based on natural estrogens |
| WO1998004268A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Oral contraceptive |
| CN1186024C (zh) | 1996-07-26 | 2005-01-26 | 惠氏公司 | 单阶段避孕方法和含有黄体酮和雌激素组合物的避孕药盒 |
| DK0921804T3 (da) * | 1996-07-26 | 2003-11-24 | Wyeth Corp | Tofase oral præventionsmetode og kit som indeholder en kombination af progestin og østrogen |
| DE19654609A1 (de) | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
| US6987101B1 (en) | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
| US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
| US6312772B1 (en) * | 1997-10-20 | 2001-11-06 | Hoechst Celanese Corporation | Multilayer laminate formed from a substantially stretched non-molten wholly aromatic liquid crystalline polymer and non-polyester thermoplastic polymer |
| DE19908762A1 (de) * | 1999-02-18 | 2000-08-31 | Jenapharm Gmbh | Verwendung von Dienogest in hoher Dosierung |
| DE10045380A1 (de) | 2000-09-14 | 2002-04-04 | Schering Ag | Verfahren zur Kontrazeption und dessen Darreichungsform |
| US6699820B2 (en) | 2001-03-02 | 2004-03-02 | Hartmut Ulrich Bielefeldt | Method for making a superconductor with enhanced current carrying capability |
| HUP0402142A2 (hu) | 2001-09-29 | 2005-02-28 | Solvay Pharmaceuticals Gmbh | Kombinációs ösztrogén-gestagen készítmény és alkalmazása |
| EP1462106A1 (en) | 2003-03-28 | 2004-09-29 | Pantarhei Bioscience B.V. | Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders |
| JP2007528358A (ja) * | 2003-06-25 | 2007-10-11 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ジエノゲストを含んでなるホルモン置換療法および抑鬱療法 |
| DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| EP2392332A1 (en) | 2004-10-07 | 2011-12-07 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
| TW200726473A (en) | 2005-06-28 | 2007-07-16 | Wyeth Corp | Compositions and methods for treatment of cycle-related symptoms |
| ATE424828T1 (de) | 2005-10-13 | 2009-03-15 | Bayer Schering Pharma Ag | Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
-
2004
- 2004-04-20 DE DE102004019743A patent/DE102004019743B4/de not_active Expired - Fee Related
-
2005
- 2005-03-09 MY MYPI20050962A patent/MY143669A/en unknown
- 2005-03-25 TW TW094109222A patent/TWI351960B/zh active
- 2005-04-15 SI SI200531115T patent/SI1740163T2/sl unknown
- 2005-04-15 ES ES05730867T patent/ES2348038T5/es active Active
- 2005-04-15 BR BRPI0510005-4A patent/BRPI0510005A/pt not_active Application Discontinuation
- 2005-04-15 KR KR1020067021681A patent/KR20060134168A/ko not_active Application Discontinuation
- 2005-04-15 ME MEP-2010-149A patent/ME01183B/me unknown
- 2005-04-15 WO PCT/EP2005/004022 patent/WO2005102247A2/de active Application Filing
- 2005-04-15 EP EP05730867.8A patent/EP1740163B2/de active Active
- 2005-04-15 PL PL05730867T patent/PL1740163T5/pl unknown
- 2005-04-15 EA EA200601844A patent/EA010313B1/ru active Protection Beyond IP Right Term
- 2005-04-15 NZ NZ550417A patent/NZ550417A/en unknown
- 2005-04-15 JP JP2007508800A patent/JP4908399B2/ja active Active
- 2005-04-15 UA UAA200611799A patent/UA83915C2/ru unknown
- 2005-04-15 PT PT05730867T patent/PT1740163E/pt unknown
- 2005-04-15 CN CN2005800125561A patent/CN1946383B/zh active Active
- 2005-04-15 DK DK05730867.8T patent/DK1740163T4/da active
- 2005-04-15 CA CA002561839A patent/CA2561839C/en active Active
- 2005-04-15 DE DE502005009904T patent/DE502005009904D1/de active Active
- 2005-04-15 AU AU2005235418A patent/AU2005235418C1/en active Active
- 2005-04-15 AT AT05730867T patent/ATE473734T1/de active
- 2005-04-15 MX MXPA06012213A patent/MXPA06012213A/es active IP Right Grant
- 2005-04-15 US US11/578,771 patent/US8071577B2/en active Active
- 2005-04-15 RS RS20100413A patent/RS51434B2/sr unknown
- 2005-04-20 AR ARP050101553A patent/AR048830A1/es not_active Application Discontinuation
- 2005-04-20 PA PA20058630901A patent/PA8630901A1/es unknown
- 2005-04-20 PE PE2005000436A patent/PE20060308A1/es not_active Application Discontinuation
- 2005-04-20 GT GT200500093A patent/GT200500093A/es unknown
- 2005-04-20 SV SV2005002090A patent/SV2006002090A/es active IP Right Grant
- 2005-04-20 UY UY28863A patent/UY28863A1/es not_active Application Discontinuation
-
2006
- 2006-10-05 IL IL178510A patent/IL178510A/en active IP Right Grant
- 2006-10-19 CR CR8695A patent/CR8695A/es unknown
- 2006-11-13 EC EC2006007000A patent/ECSP067000A/es unknown
- 2006-11-17 NO NO20065292A patent/NO344098B1/no unknown
- 2006-11-17 ZA ZA2006/09594A patent/ZA200609594B/en unknown
-
2007
- 2007-07-03 HK HK07107104.1A patent/HK1099701A1/xx unknown
-
2010
- 2010-03-18 US US12/726,799 patent/US20100173877A1/en not_active Abandoned
- 2010-09-17 HR HRP20100513TT patent/HRP20100513T4/hr unknown
- 2010-10-14 CY CY20101100913T patent/CY1111292T1/el unknown
-
2011
- 2011-02-04 US US13/020,913 patent/US20110124612A1/en not_active Abandoned
- 2011-12-12 AR ARP110104615A patent/AR084229A2/es not_active Application Discontinuation
-
2015
- 2015-07-09 IL IL239861A patent/IL239861A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1946383A (zh) | 基于天然雌激素的多段式避孕制剂 | |
| JP6153967B2 (ja) | 延長されたホルモン避妊法における破綻出血の管理 | |
| FI103951B (fi) | Ehkäisyjärjestelmä | |
| US8461138B2 (en) | Quadraphasis continuous graduated estrogen contraceptive | |
| US6884793B2 (en) | Combination preparation for contraception based on natural estrogens | |
| AU716249B2 (en) | Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen | |
| JP2019163318A5 (zh) | ||
| CN1133011A (zh) | 含有至少一种孕激素和至少一种雌激素的替代治疗用制剂 | |
| EP0912186A1 (en) | Progestogen-anti-progestogen regimens | |
| CN1077430C (zh) | 激素避孕法的药物复合制剂 | |
| CA2309745A1 (en) | Progestogen-antiprogestogen regimens | |
| AU2011226911B2 (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens | |
| ZA200609988B (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1099701 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1099701 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER PHARMA AG Effective date: 20130730 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: BAYER PHARMA AG Free format text: FORMER NAME: SCHERING AG |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Berlin Patentee after: BAYER PHARMA AG Address before: Berlin Patentee before: BAYER SCHERING PHARMA AG |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130730 Address after: German Monheim Patentee after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Berlin Patentee before: Bayer Pharma AG |
|
| CP02 | Change in the address of a patent holder |
Address after: 50 Alfred Nobel Street, 40789 Monheim on the Rhine, Germany Patentee after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Germany Patentee before: BAYER INTELLECTUAL PROPERTY GmbH |
|
| CP02 | Change in the address of a patent holder |